Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. With relapse rates as high as 50%, routine measurable residual disease (MRD) ...
The presentation "Measurable Residual Disease in AML using Oncomine NGS analysis" by Dr. Jong-Mi Lee from the College of Medicine at The Catholic University of Korea explores the application of ...
Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
NATICK, Mass., March 3, 2026 /PRNewswire/ -- Pillar Biosciences today announced the launch of the oncoReveal ® Rapid AML Panel, a focused research-use-only (RUO) DNA next-generation sequencing (NGS) ...
AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of increased ...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...
With the advent of next-generation sequencing (NGS), it may be possible to better understand and characterize potential risk associated in AML at the time of diagnosis as it relates to various ...
The prognosis of NF1 mutations in newly diagnosed AML: A single-center retrospective study. A novel thrombopoietin mimetic RWJ-800088 increases megakaryopoiesis without causing malignant proliferation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results